

May 30th

Case-Based Panel 1:00 PM CDT Arie Crown Theater |

ctDNA Guiding Treatment of Colorectal Cancer: Ready for Primetime?

Primary Track: Gastrointestinal Cancer—Colorectal and Anal

Medical Oncologist Perspective

Chloe E. Atreya, MD, PhD

Oral Abstract Session May 30 – 2:45 PM CDT. Hall D1 |

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.

5:09 PM CDT **Silver Alkhafaji, BS** Abstract 3008

May 31st

Oral Abstracts Session

Pediatric Oncology I S100bc | Live Stream

May 31, 2025. 3:00 PM – 6:00 PM CDT

Co-Chair Amit J. Sabnis, MD

Rapid Oral Abstracts Session

Care Delivery/Models of Care S402 | On Demand

Co-Chair Rebecca Jane DeBoer, MD, MA

POSTERS

9:00 AM CDT. Hall A - Posters and Exhibits |

Poster Session

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Real-world predictors of adverse clinical outcomes in pancreatic cancer using a machine-learning framework.

Presenter: **Akanksha Dua** | University of California, San Francisco

Abstract: 4186 | Poster Bd #: 476

Central Nervous System Tumors

Identification of novel electrophysiologic biomarkers of cognition in glioma-infiltrated cortex.

Vardhaan Ambati, MS | University of California, San Francisco

Abstract 2077 | Poster 123

Quality Care/Health Services Research

Identifying multi-level social determinants for disparities in survival and patient-reported outcomes in national head and neck cancer trials.

Sue S. Yom, MD, PhD | UCSF Medical Center-Mount Zion

Abstract 11066 | Poster 405

June 1st

Clinical Science Symposium 8:36 AM CDT S402

Global Cancer Care Delivery: Resiliency in the Face of Conflict and Resource Constraints

Primary Track: Care Delivery and Quality Care

Analysis of evidence in NCCN harmonized guidelines for sub-Saharan Africa.

Scott Swartz, MD, MS | Department of Medicine, University of California, San Francisco

Abstract: 1510

Clinical Science Symposium 9:45 AM CDT E350 | On Demand

Refining Local Therapies in Central Nervous System Oncology: Hitting the Bullseye

Primary Track: Central Nervous System Tumors

Amit Sabnis Co-Chair

Clinical Science Symposium 4:30 PM CDT Arie Crown Theater

The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium Supported by the Breast Cancer Research Foundation: ctDNA for Breast Cancer: It's Here—Are We Ready?

Jo Chien, MD | University of California, San Francisco Helen Diller Family Comprehensive Cancer Center

Rapid Oral Abstract Session. 11:15 AM CDT. S406 | On Demand

Developmental Therapeutics—Immunotherapy

Tumor-wide RNA splicing aberrations and their potential as therapeutic neoantigen targets.

Darwin Kwok, PhD, MS Abstract 2519

POSTERS

Genitourinary Cancer—Prostate, Testicular, and Penile

A randomized, open-label, phase 2b study of the BET bromodomain inhibitor (BETi) ZEN-3694 plus enzalutamide vs. enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC).

Presenter: **Rahul Raj Aggarwal, MD** | University of California, San Francisco

Abstract: TPS5123 | Poster Bd #: 315b

External validation of a pathology-based multimodal artificial intelligence biomarker for predicting prostate cancer outcomes after prostatectomy.

Presenter: **Chien-Kuang Cornelia Ding, MD, PhD** | University of California, San Francisco

Abstract: 5106. | Poster Bd #: 305

Melanoma/Skin Cancers

A phase II study of binimetinib plus imatinib in patients with unresectable KIT-mutant melanoma.

Katy K. Tsai, MD | UCSF

Abstract: TPS9605 | **Poster Bd #:** 81b

June 2nd

Oral Abstract Session 10:36 AM CDT S504

Pediatric Oncology II

Preserving Young Minds: Where to Go in Pediatric Neuro-Oncology

Anuradha Banerjee, MD | University of California, San Francisco

Oral Abstract Session 2 – 3:00 PM CDT Hall B1

4:12 PM CDT

Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial.

Presenter: **Rita Mukhtar, MD** | Division of Surgical Oncology, Department of Surgery, University of California, San Francisco

Abstract: 504

Education Session 4:45 PM E451

State of the Art in Care of Hepatobiliary Malignancies

- 5:00 PM CDT State of the Science in the Management of Hepatocellular Carcinoma

Speaker: **Robin Kate Kelley, MD** | University of California San Francisco

POSTERS: 9:00 AM CDT Hall A - Posters and Exhibits |

Genitourinary Cancer—Kidney and Bladder

Circulating tumor DNA (ctDNA) monitoring in patients (pts) with advanced urothelial carcinoma (aUC) treated with enfortumab vedotin +/- pembrolizumab (EVP).

Presenter: **Kevin R Reyes, BS** | University of California, San Francisco

Abstract: 4560 | Poster Bd #: 360

Prognostic utility of ctDNA before and after trimodality therapy (TMT) for muscle invasive bladder cancer.

Presenter: **Brendan Raizenne, MD** | University of California, San Francisco

Abstract: 4578 | Poster Bd #: 378

A phase 2, open-label, randomized study of livmoniplimab in combination with budigalimab versus chemotherapy in patients with metastatic urothelial carcinoma.

Presenter: **Terence W. Friedlander, MD** | University of California, San Francisco Medical Center

Abstract: TPS4618 | Poster Bd #: 414b

Head and Neck Cancer

Real world utilization of comprehensive genomic profiling (CGP) in head and neck squamous cell carcinoma (SCCHN).

Presenter: **Connie Jiayu Zhou, MD** | University of California, San Francisco

Abstract: 6021 | Poster Bd #: 429

Breast Cancer—Local/Regional/Adjuvant

Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).

Presenter: **Jo Chien, MD** | University of California, San Francisco

Abstract: 604 | Poster Bd #: 197

Reframing hormone-positive DCIS management: Effects of adjuvant therapies and surgical extent on any invasive recurrence.

Presenter: **Thomas O'Keefe** | University of California, San Francisco

Abstract: 572 | Poster Bd #: 165

Early adverse symptoms to predict response to treatment among patients in the I-SPY trial.

Presenter: **Amrita Basu, PhD** | University of California, San Francisco

Abstract: 610 | Poster Bd #: 203

RECAST (Re-Evaluating Conditions for Active Surveillance Suitability as Treatment) for DCIS: Clinical trial in progress.

Presenter: **Ruolin Lorraine Jiang, BS** | University of California, San Francisco

Abstract: TPS624 | Poster Bd #: 212b

June 2 – 1:30 PM CDT Hall A - Posters and Exhibits |

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Real-time clinical validation of a blood cell-free, mRNA-based GeneVerify test for screening and early diagnosis of prostate cancer.

Presenter: **Rajvir Dahiya, PhD, DSci** | University of California at San Francisco School of Medicine (UCSF)

Abstract: 3053 | Poster Bd #: 368

Symptom Science and Palliative Care

Multisite validation of biomechanical computed tomography for osteoporosis assessment and fracture prediction in patients with high-risk or metastatic prostate cancer.

Presenter: **Samuel L. Washington, MD** | Department of Urology, University of California, San Francisco

Abstract: 12044 | Poster Bd #: 64

Multidisciplinary and multi-institutional cancer symptom management strategies in the Veterans Affairs: A mixed methods study.

Presenter: **Johanna Balas, MD** | University of California San Francisco

Abstract: 12076 | Poster Bd #: 96

Medical Education and Professional Development

Evaluation of NCI Designated Cancer Centers medical student education and training initiatives.

Presenter: **Ana I. Velazquez Manana, MD, FASCO, MSc** | University of California, San Francisco

Abstract: 9032 | Poster Bd #: 21

June 3rd

Oral Abstract Session - Hall D1. 9:45 am

Genitourinary Cancer—Prostate, Testicular, and Penile

Tailoring Therapy in Castration-Sensitive Prostate Cancer: Do Biomarkers Make the Cut?

Rahul Raj Aggarwal, MD